Thrombin receptor PAR4 cross-activates the tyrosine kinase c-met in atrial cardiomyocytes

被引:1
|
作者
Mittendorff, Claudia [1 ]
Abu-Taha, Issam [1 ]
Kassler, Lena [1 ]
Hustedt, Tobias [2 ,3 ]
Wolf, Stephanie [2 ,3 ]
Bode, Johannes G. [2 ,3 ]
Kamler, Markus [4 ]
Dobrev, Dobromir [1 ,5 ,6 ,7 ,8 ]
Fender, Anke C. [1 ]
机构
[1] Univ Duisburg Essen, Inst Pharmacol, West German Heart & Vasc Ctr, Duisburg, Germany
[2] Heinrich Heine Univ, Fac Med, Dept Gastroenterol Hepatol & Infect Dis, Dusseldorf, Germany
[3] Heinrich Heine Univ, Dusseldorf Univ Hosp, Dusseldorf, Germany
[4] Univ Hosp Essen, Dept Thorac & Cardiovasc Surg, Essen, Germany
[5] Montreal Heart Inst, Dept Med, Montreal, PQ, Canada
[6] Montreal Heart Inst, Res Ctr, Montreal, PQ, Canada
[7] Univ Montreal, Montreal, PQ, Canada
[8] Baylor Coll Med, Dept Integrat Physiol, Houston, TX USA
基金
美国国家卫生研究院;
关键词
Atrial; Cardiomyocyte; C-met; NLRP3; inflammasome; Protease-activated receptor; Thrombin; EXPRESSION; TARGET; CELLS;
D O I
10.1007/s00210-024-03436-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Thrombin supports coagulation-independent inflammation via protease-activated receptors (PAR). PAR4 is specifically increased in obese human atria, correlating with NLRP3 inflammasome activation. PAR4-mediated NLRP3 inflammasome activation in atrial cardiomyocytes is not known, nor have signaling partners been identified. Thrombin transactivates the hepatocyte growth factor receptor in some cancer cells, so we examined PAR4/c-met cross-talk in atrial cardiomyocytes and its possible significance in obesity. Cardiomyocytes from right atrial appendages (RAA) of obese patients expressed more PAR1 and PAR4 compared to non-obese. In HL-1 atrial cardiomyocytes, thrombin induced caspase-1 auto-activation and IL-1 beta maturation; IL-1 beta secretion was evoked by PAR4-activating peptide (AP), but not PAR1-AP. PAR4-AP additionally increased phosphorylated CaMKII-Thr287, mTOR-Ser2481, and Akt-Ser473 while suppressing AMPK-Thr172 phosphorylation. Total kinase levels were largely unaltered. PAR4AP rapidly increased phosphorylated c-met in HL-1 cells and over time also transcriptionally upregulated c-met. The c-met inhibitor SGX-523 abrogated the effects of PAR4-AP on CaMKII/AKT/mTOR phosphorylation but did not affect PAR4-stimulated IL-1 beta production. Obese human RAA contained more IL-1 beta, phospho-c-met, and phospho-mTOR than non-obese RAA; CamKII phosphorylation was not modified. Atria from high-fat diet (HFD) versus chow-fed mice also contained more IL-1 beta, together with higher myeloperoxidase activity, Acta2 mRNA total and phosphorylated c-met; these increases were blunted in PAR4-/- HFD-fed mice. Thrombin cross-activates c-met via PAR4 in atrial cardiomyocytes. Transactivated c-met contributes partially to PAR4-mediated signaling, but NLRP3 inflammasome activation appears to be largely independent of c-met. Abundance of PAR4 and activated c-met increases with obesity, providing therapeutic targets for management of adiposity-driven AF.
引用
收藏
页码:2783 / 2796
页数:14
相关论文
共 50 条
  • [31] Differential requirements for the receptor tyrosine kinase c-Met in scirrhous gastric carcinoma cell lines
    Yoshida, Nachi
    Yamaguchi, Hideki
    Muroi, Emi
    Takanashi, Miho
    Fukami, Kiyoko
    Sakai, Ryuichi
    CANCER RESEARCH, 2012, 72
  • [32] Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy
    Glodde, Nicole
    Bald, Tobias
    van den Boorn-Konijnenberg, Debby
    Nakamura, Kyohei
    O'Donnell, Jake S.
    Szczepanski, Sabrina
    Brandes, Maria
    Eickhoff, Sarah
    Das, Indrajit
    Shridhar, Naveen
    Hinze, Daniel
    Rogava, Meri
    van der Sluis, Tetje C.
    Ruotsalainen, Janne J.
    Gaffal, Evelyn
    Landsberg, Jennifer
    Ludwig, Kerstin U.
    Wilhelm, Christoph
    Riek-Burchardt, Monika
    Mueller, Andreas J.
    Gebhardt, Christoffer
    Scolyer, Richard A.
    Long, Georgina V.
    Janzen, Viktor
    Teng, Michele W. L.
    Kastenmueller, Wolfgang
    Mazzone, Massimiliano
    Smyth, Mark J.
    Tueting, Thomas
    Hoelzel, Michael
    IMMUNITY, 2017, 47 (04) : 789 - +
  • [33] c-Met receptor tyrosine kinase: A novel molecular therapeutic target for the treatment of pancreatic cancer
    Jagadeeswaran, Ramasamy
    Ahmed, Salman
    Janamanchi, Varalakshmi
    Surawska, Hanna
    Karikari, Collins
    Maitra, Anirban
    Salgia, Ravi
    CANCER RESEARCH, 2006, 66 (08)
  • [34] Receptor tyrosine kinase c-Met controls the cytoskeleton from different endosomes via different pathways
    Menard, Ludovic
    Parker, Peter J.
    Kermorgant, Stephanie
    NATURE COMMUNICATIONS, 2014, 5
  • [35] Receptor tyrosine kinase c-Met controls the cytoskeleton from different endosomes via different pathways
    Ludovic Ménard
    Peter J. Parker
    Stéphanie Kermorgant
    Nature Communications, 5
  • [36] A common p53 mutation (R175H) activates c-Met receptor tyrosine kinase to enhance tumor cell invasion
    Grugan, Katharine D.
    Vega, Maria E.
    Wong, Gabrielle S.
    Diehl, J. Alan
    Bass, Adam J.
    Wong, Kwok K.
    Nakagawa, Hiroshi
    Rustgi, Anil K.
    CANCER BIOLOGY & THERAPY, 2013, 14 (09) : 853 - 859
  • [37] Nuclear receptor tyrosine kinase c-MET restrains efficacy of PARP inhibitor in pancreatic cancer cells
    Gao, Yuan
    Chen, Mei-Kuang
    Yu, Dihua
    Hung, Mien-Chie
    CANCER RESEARCH, 2020, 80 (16)
  • [38] Immunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-Met, and EGFR in skull base chordoma
    Akhavan-Sigari, R.
    Abili, M.
    Gaab, M. R.
    Rohde, V.
    Zafar, N.
    Emami, P.
    Ostertag, H.
    NEUROSURGICAL REVIEW, 2015, 38 (01) : 89 - 98
  • [39] Disrupting c-Met receptor tyrosine kinase activation as adjuvant therapy for hormone refractory prostate cancer
    Tu, William
    Zhu, Chunfang
    Christensen, James
    Sun, Zijie
    CANCER RESEARCH, 2009, 69
  • [40] A c-Met receptor tyrosine kinase inhibitor offers increased radiosensitization in NSCLC after pretreatment with Erlotinib
    Welsh, James
    Ellsworth, Ron
    Mahadevan, Daruka
    Bearss, David
    Komaki, Ritsuko
    Stea, Baldassarre
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S957 - S958